SCHEMBL3830180

SCHEMBL3830180

CC(C)(C)OC(=O)NC1CC(OCc2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KDM1A O60341 1/20 0.50
MAOB P27338 1/20 0.50
EPHX2 P34913 2/20 0.47
KLK5 Q9Y337 4/20 0.46
KLK7 P49862 4/20 0.46
KCNA3 P22001 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
BTK Q06187 1/20 0.44
SYK P43405 1/20 0.44
PPARA Q07869 1/20 0.44
DRD2 P14416 1/20 0.42
AKT1 P31749 2/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3830184 1.00 KMT2A (0.60) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL9430749 1.00 KMT2A (0.60) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL25978594 0.90 KMT2A (0.48) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL31529319 0.90 KMT2A (0.48) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL31284769 0.89 KMT2A (0.60) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL23185762 0.88 KMT2A (0.50) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL3200317 0.88 KMT2A (0.56) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL30143734 0.88 KMT2A (0.50) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL3200309 0.88 KMT2A (0.56) KMT2AL3MBTL1KDM1AMAOBEPHX2
SCHEMBL22849420 0.87 KMT2A (0.46) KMT2AL3MBTL1KDM1AMAOBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021061823-A1 CHEMICAL COMPOUNDS Boragen, Inc. (US) 2021-04-01 WO disclosed
US-20160280703-A1 Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors AMGEN INC. 2016-09-29 US disclosed
US-8952037-B2 Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
EP-2655320-A1 PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND GE Healthcare UK Limited (GB) 2013-10-30 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
WO-2012084794-A1 PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND GE HEALTHCARE LIMITED (GB) 2012-06-28 WO disclosed
US-20110306591-A1 HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS INC., AMGEN 2011-12-15 US disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 US disclosed
EP-2103619-A1 IMIDAZOTHIAZOLE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-09-23 EP disclosed
US-5567726-A SELECTIVE AGONISTS OF 5-HYDROXYTRYPTAMINE-LIKE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS MERCK, SHARP & DOHME LTD. (GB) 1996-10-22 US disclosed
EP-0651749-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1995-05-10 EP disclosed
WO-1994002477-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 KMT2A 4182/4885L3MBTL1 4139/4885KDM1A 4284/4885
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 KMT2A 1259/4885L3MBTL1 299/4885KDM1A 1848/4885
US-20110306591-A1 HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS PDE10A, PDE9A, HDAC10 KMT2A 2027/4885L3MBTL1 3881/4885KDM1A 1810/4885
US-20160280703-A1 Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors PDE10A, PDE9A, PDE7A KMT2A 1997/4885L3MBTL1 3929/4885KDM1A 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.